{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-007703","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2024-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.746092+00:00","generated_at":"2026-06-06T16:34:52.645031+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corbus announces Phase 1 data for CRB-701: 43% ORR at therapeutic doses, no peripheral neuropathy or skin rash","bullets":["Phase 1 dose-escalation data for CRB-701 (SYS6002) in nectin-4 positive tumors presented at ASCO GU 2024.","At doses ≥2.7 mg/kg (n=7), ORR 43% (3 partial responses) and disease control rate 71%; no grade 3+ adverse events.","No dose-limiting toxicities, peripheral neuropathy, or skin rash observed; dose escalation ongoing at 4.5 mg/kg.","CRB-701 showed lower free MMAE exposure vs enfortumab vedotin; longest ongoing response ~10 months.","U.S. clinical study expected to start in Q1 2024 under already-open IND."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-007703","json":"https://secwatch.observer/filing/0000950170-24-007703.json","markdown":"https://secwatch.observer/filing/0000950170-24-007703.md","text":"https://secwatch.observer/filing/0000950170-24-007703.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024007703/0000950170-24-007703-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024007703/crbp-20240126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T16:34:52.645031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}